A rare sponsor victory on an appeal of a complete response letter for Ardelyx Inc.’s phosphate absorption inhibitor Xphozah (tenapanor) could embolden other sponsors to pursue dispute resolution when a US Food and Drug Administration review division concludes a drug is not approvable based upon currently available evidence.
On 29 December, Ardelyx announced that the Office of New Drugs (OND) granted its appeal of the June 2021 CRL...








